On February 11, 2011 Axcan completed the acquisition of Eurand N.V., a global specialty pharmaceutical company. The new company began its combined operations on February 14, 2011, and has announced its new name, Aptalis™, on May 4, 2011. Aptalis is a leading international specialty pharmaceutical company that develops, manufactures, markets and distributes cystic fibrosis and gastroenterology products and therapeutic treatments. We have offices in United States, Europe and Canada, as well as sales representatives throughout North America and Europe.
We are positioned to expand globally and diversify our portfolio of in-market products and pipeline candidates, while enhancing our world-class commercial, manufacturing, drug formulation and R&D capabilities.
Manufacturing and Industrial Transformation
